Antineoplastic - CAR-T/TCR-T cell immunotherapy

The phrase "Antineoplastic - CAR-T/TCR-T cell immunotherapy" is an administrative and compendial drug-classification category used in electronic health record databases and drug formularies to group genetically engineered, adoptive T-cell therapies

The phrase "Antineoplastic - CAR-T/TCR-T cell immunotherapy" is an administrative and compendial drug-classification category used in electronic health record databases and drug formularies to group genetically engineered, adoptive T-cell therapies

Products assigned to this class consist of patient-derived or donor lymphocytes modified to express synthetic chimeric antigen receptors (CARs) or engineered T-cell receptors (TCRs) that recognize specific tumor-associated antigens and drive targeted cytolytic immune responses Clinically, these cellular therapies serve as potent antineoplastic agents primarily utilized for treatment-refractory hematologic malignancies—such as B-cell leukemias, non-Hodgkin lymphomas, and multiple myeloma—as well ...

Products assigned to this class consist of patient-derived or donor lymphocytes modified to express synthetic chimeric antigen receptors (CARs) or engineered T-cell receptors (TCRs) that recognize specific tumor-associated antigens and drive targeted cytolytic immune responses Clinically, these cellular therapies serve as potent antineoplastic agents primarily utilized for treatment-refractory hematologic malignancies—such as B-cell leukemias, non-Hodgkin lymphomas, and multiple myeloma—as well ...

Products assigned to this class consist of patient-derived or donor lymphocytes modified to express synthetic chimeric antigen receptors (CARs) or engineered T-cell receptors (TCRs) that recognize specific tumor-associated antigens and drive targeted cytolytic immune responses

Clinically, these cellular therapies serve as potent antineoplastic agents primarily utilized for treatment-refractory hematologic malignancies—such as B-cell leukemias, non-Hodgkin lymphomas, and multiple myeloma—as well as select advanced solid tumors like synovial sarcoma